2024

1. Risk versus Benefit of Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

   Clinical Pharmacology and Therapeutics, Vol. 116, Núm. 2, pp. 328-345